清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial

拜瑞妥 阿哌沙班 医学 达比加群 内科学 倾向得分匹配 心房颤动 冲程(发动机) 华法林 观察研究 机械工程 工程类
作者
Yeela Talmor‐Barkan,Nancy‐Sarah Yacovzada,Hagai Rossman,Guy Witberg,Iris N. Kalka,Ran Kornowski,Eran Segal
出处
期刊:European Heart Journal - Cardiovascular Pharmacotherapy [Oxford University Press]
卷期号:9 (1): 26-37 被引量:31
标识
DOI:10.1093/ehjcvp/pvac063
摘要

AIMS: The advantages of direct oral anticoagulants (DOACs) over warfarin are well established in atrial fibrillation (AF) patients, however, studies that can guide the selection between different DOACs are limited. The aim was to compare the clinical outcomes of treatment with apixaban, rivaroxaban, and dabigatran in patients with AF. METHODS AND RESULTS: We conducted a retrospective, nationwide, propensity score-matched-based observational study from Clalit Health Services. Data from 141 992 individuals with AF was used to emulate a target trial for head-to-head comparison of DOACs therapy. Three-matched cohorts of patients assigned to DOACs, from January-2014 through January-2020, were created. One-to-one propensity score matching was performed. Efficacy/safety outcomes were compared using KaplanMeier survival estimates and Cox proportional hazards models. The trial included 56 553 patients (apixaban, n = 35 101; rivaroxaban, n = 15 682; dabigatran, n = 5 770). Mortality and ischaemic stroke rates in patients treated with rivaroxaban were lower compared with apixaban (HR,0.88; 95% CI,0.78-0.99; P,0.037 and HR 0.92; 95% CI,0.86-0.99; P,0.024, respectively). No significant differences in the rates of myocardial infarction, systemic embolism, and overall bleeding were noticed between the different DOACs groups. Patients treated with rivaroxaban demonstrated lower rate of intracranial haemorrhage compared with apixaban (HR,0.86; 95% CI,0.74-1.0; P,0.044). The rate of gastrointestinal bleeding in patients treated with rivaroxaban was higher compared with apixaban (HR, 1.22; 95% CI,1.01-1.44; P, 0.016). CONCLUSION: We demonstrated significant differences in outcomes between the three studied DOACs. The results emphasize the need for randomized controlled trials that will compare rivaroxaban, apixaban, and dabigatran in order to better guide the selection among them.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大胆半双完成签到,获得积分10
4秒前
安详冰夏完成签到,获得积分10
18秒前
传奇3的应助被yiyixt采纳,获得10
19秒前
22秒前
喵喵发布了新的文献求助10
26秒前
风趣馒头完成签到,获得积分10
29秒前
喵喵完成签到 ,获得积分10
36秒前
月儿完成签到 ,获得积分0
46秒前
酷炫安雁完成签到,获得积分10
51秒前
52秒前
zy997987876完成签到,获得积分10
53秒前
舒心的以莲完成签到,获得积分10
1分钟前
1分钟前
369ninja发布了新的文献求助30
1分钟前
合适的太英完成签到,获得积分10
1分钟前
muyicccccc完成签到 ,获得积分10
2分钟前
潇洒小海豚完成签到,获得积分10
2分钟前
2分钟前
谦让大米完成签到,获得积分10
2分钟前
2分钟前
无辜摇伽完成签到,获得积分10
2分钟前
2分钟前
2分钟前
2分钟前
2分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
Perse完成签到,获得积分10
3分钟前
3分钟前
Perse发布了新的文献求助20
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179961
求助须知:如何正确求助?哪些是违规求助? 9570183
关于积分的说明 21808480
捐赠科研通 7775832
什么是DOI,文献DOI怎么找? 3433251
关于科研通互助平台的介绍 2557373
邀请新用户注册赠送积分活动 2478958